Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017316 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00017316: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00017316 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017316, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating patients who have metastatic melanoma. Thalidomide combined with SU5416 may stop the growth of metastatic melanoma by stopping blood flow to the tumor.
Interventions
- DRUG semaxanib
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017316
The ClinicalTrials.gov registry entry for NCT00017316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which semaxanib is the first listed.
NCT00017316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017316 about?
NCT00017316 is a clinical study titled "Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma". Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating patients who have metastatic melanoma. Thalidomide combined with SU5416 may stop the growth of metastatic melanoma by stopping blood flow to the tumor.
What is the current status of trial NCT00017316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-03.
What interventions are being tested in trial NCT00017316?
The interventions under investigation include: semaxanib (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00017316?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.